Science Archives (2026) Vol. 7 (2), 192-203

Science Archives (ISSN:2582-6697)

Journal homepage: www.sciencearchives.org

DOI: hhttps://doi.org/10.47587/SA.2026.7218

Research Article

Precision Oncology: How Targeted Therapies Based on Tumor Genomics Improve Treatment Outcomes

Stella Ehi Egege[1], Micheal Abimbola Oladosu[2*], Moses Adondua Abah[3], Bukola Oluwaseyi Olufosoye[4] and Chinwe Dolly Udeka[5]

[1]Faculty of Medicine, The International University of the Health Sciences, Basseterre, St. Kitts, West Indies
[2]Department of Chemical Sciences, Faculty of Science, Anchor University, Lagos, Nigeria.
[3]Department of Biochemistry, Faculty of Pure and Applied Sciences, Federal University of Wukari, Wukari, Taraba State, Nigeria
[4]Department of Medical Microbiology, Faculty of Medical Laboratory Sciences. Ambrose Alli University, Ekpoma, Edo State, Nigeria
[5]Department of Pharmacy Technician, Faculty of Pharmaceutical Sciences, Mbash College of Health Sciences and Technology, Abia State, Nigeria

***Corresponding Author**

Received: Apr 28, 2026/ Revised: May 29, 2026/Accepted: June 5, 2026

Abstract

Precision oncology represents a paradigm shift in cancer treatment, leveraging tumor genomic profiling to guide therapeutic decisions. The integration of next-generation sequencing technologies has revolutionized our understanding of cancer biology and enabled the development of targeted therapies that specifically address oncogenic driver mutations. This review examines the current landscape of precision oncology, focusing on how targeted therapies based on tumor genomics improve treatment outcomes across various cancer types. We discuss the molecular mechanisms underlying targeted therapies, including tyrosine kinase inhibitors, monoclonal antibodies, and immune checkpoint inhibitors. The clinical applications of comprehensive genomic profiling, liquid biopsy technologies, and biomarker-driven patient selection are critically evaluated. Furthermore, we explore emerging challenges including acquired resistance mechanisms, tumor heterogeneity, and accessibility issues in resource-limited settings. Recent advances in artificial intelligence-guided drug discovery and combination therapeutic strategies are also highlighted. Evidence demonstrates that genomically-matched targeted therapies significantly improve progression-free survival, overall survival, and quality of life compared to conventional chemotherapy in appropriately selected patients. However, several barriers to widespread implementation persist, including high costs, limited access to molecular diagnostics, and the need for multidisciplinary expertise. This review provides a comprehensive overview of precision oncology's transformative impact on cancer care and discusses future directions for optimizing treatment outcomes through genomics-guided therapeutic interventions.

Keywords: *Precision oncology; Targeted therapy; Tumor genomics; Next-generation sequencing; Biomarkers; Personalized medicine*

INREODUCTION

Cancer remains one of the leading causes of mortality worldwide, with approximately 19.3 million new cases and 10 million cancer-related deaths reported in 2020 [1]. Traditional cancer treatment approaches, including surgery, radiotherapy, and cytotoxic chemotherapy, have achieved significant successes but are often limited by systemic toxicity, non-selective action, and development of therapeutic resistance [2]. The advent of precision oncology has fundamentally transformed cancer care by shifting from empirical, one-size-fits-all treatment paradigms to individualized, molecularly-informed therapeutic strategies [3].

Precision oncology, also termed personalized or genomic medicine, is predicated on the principle that each patient's tumor possesses a unique molecular signature that can be exploited for therapeutic benefit [4]. The Human Genome Project's completion in 2003 and subsequent technological advances in next-generation sequencing (NGS) have enabled comprehensive characterization of cancer genomes at unprecedented resolution and decreasing costs [5]. These genomic insights have revealed that cancers are fundamentally genetic diseases driven by acquired somatic mutations, chromosomal rearrangements, copy number alterations, and epigenetic modifications [6].

The molecular heterogeneity of cancer has profound implications for treatment selection. Tumors historically classified by organ of origin and histopathology are now recognized to comprise molecularly distinct subtypes with different prognoses and therapeutic vulnerabilities [7]. For instance, breast cancer encompasses at least four major molecular subtypes—luminal A, luminal B, HER2-enriched, and basal-like—each requiring distinct therapeutic approaches [8]. Similarly, lung adenocarcinomas harbor diverse oncogenic drivers including EGFR mutations, ALK rearrangements, ROS1 fusions, BRAF mutations, and MET amplifications, each targetable with specific inhibitors [9].

Targeted therapies, designed to selectively interfere with specific molecular pathways essential for cancer cell survival and proliferation, represent the cornerstone of precision oncology [10]. Unlike conventional chemotherapy that indiscriminately damages rapidly dividing cells, targeted agents exploit cancer-specific vulnerabilities while sparing normal tissues, thereby improving therapeutic indices [11].

The success of targeted therapies such as imatinib for chronic myeloid leukemia, trastuzumab for HER2-positive breast cancer, and crizotinib for ALK-positive lung cancer has validated the precision oncology paradigm and spurred development of numerous molecularly-targeted agents [12].
This review comprehensively examines how targeted therapies based on tumor genomics improve treatment outcomes in contemporary oncology practice. We discuss molecular diagnostic technologies, classes of targeted therapeutics, clinical applications across cancer types, mechanisms of resistance, and future directions for optimizing precision oncology approaches.

MOLECULAR DIAGNOSTIC TECHNOLOGIES IN PRECISION ONCOLOGY

Next-Generation Sequencing and Comprehensive Genomic Profiling

Next-generation sequencing has emerged as the gold standard for comprehensive tumor genomic characterization, enabling simultaneous analysis of multiple genes for various alteration types including single nucleotide variants, insertions/deletions, copy number changes, and structural rearrangements [13]. Commercial NGS-based comprehensive genomic profiling (CGP) assays such as FoundationOne CDx, MSK-IMPACT, and Tempus xT have been clinically validated and FDA-approved for identifying actionable genomic alterations across solid tumors [14].

The clinical utility of CGP has been demonstrated in multiple prospective studies. The NCI-MATCH trial evaluated targeted therapy assignment based on tumor genomic profiling across diverse cancer types, revealing that approximately 37% of patients harbored actionable mutations, with 18% successfully matched to targeted therapies [15]. Similarly, the MOSCATO-01 trial demonstrated that genomically-matched therapies yielded superior outcomes compared to unmatched treatments, with improved progression-free survival ratios [16].

Table 1: Comparison of Comprehensive Genomic Profiling Platforms in Clinical Use

Platform	Technology	Genes Analyzed	Alteration Types Detected	Tissue Requirement	FDA Approval Status	Key Clinical Applications
FoundationOne CDx	Hybrid-capture NGS	324 genes + selected rearrangements	SNVs, indels, CNAs, rearrangements, MSI, TMB	FFPE tissue (≥40 mm²)	FDA-approved CDx	Solid tumors; companion diagnostics for multiple targeted therapies
MSK-IMPACT	Hybridization-capture NGS	468–505 genes	SNVs, indels, CNAs, fusions, MSI	FFPE tissue or blood	NYS-approved	Solid and hematologic malignancies; clinical trial matching
Tempus xT	Hybrid-capture NGS	648 genes	SNVs, indels, CNAs, rearrangements, RNA fusions	FFPE tissue	Laboratory Developed Test (LDT)	Solid tumors; comprehensive profiling with transcriptome analysis
Guardant360 CDx	Digital sequencing (liquid biopsy)	74 genes	SNVs, indels, CNAs, fusions	Plasma (1–2 tubes)	FDA-approved CDx	Non-invasive profiling; monitoring; NSCLC first-line therapy selection
Caris MI Profile	Multi-platform	592 genes (DNA) + protein/RNA	SNVs, indels, CNAs, IHC, RNA expression	FFPE tissue	Laboratory Developed Test (LDT)	Solid tumors; integrated molecular profi

Abbreviations: NGS, next-generation sequencing; SNVs, single nucleotide variants; indels, insertions/deletions; CNAs, copy number alterations; MSI, microsatellite instability; TMB, tumor mutational burden; FFPE, formalin-fixed paraffin-embedded; CDx, companion diagnostic; LDT, laboratory-developed test; IHC, immunohistochemistry; NSCLC, non-small cell lung cancer; NYS, New York State

Liquid Biopsy and Circulating Tumor DNA Analysis

Liquid biopsy technologies have revolutionized precision oncology by enabling non-invasive tumor genomic profiling through analysis of circulating tumor DNA (ctDNA) in peripheral blood [17]. Unlike tissue biopsies that sample a single tumor region, ctDNA potentially represents the complete tumor genomic landscape across primary and metastatic sites, addressing issues of spatial and temporal heterogeneity (18). FDA-approved liquid biopsy assays including Guardant360 CDx and FoundationOne Liquid CDx demonstrate high concordance with tissue-based testing for detecting actionable alterations [19].

Clinical applications of liquid biopsy extend beyond initial diagnosis to include monitoring treatment response, detecting minimal residual disease, identifying resistance mechanisms, and screening for early cancer detection [20]. The LIBRETTO-001 trial utilized ctDNA analysis to identify patients with RET fusion-positive solid tumors eligible for selpercatinib therapy, demonstrating the feasibility of liquid biopsy-guided targeted therapy selection [21]. Additionally, serial ctDNA monitoring enables real-time assessment of tumor dynamics and early detection of acquired resistance mutations, facilitating timely treatment modifications [22].

Biomarker-Driven Patient Selection

Predictive biomarkers are essential for identifying patients most likely to benefit from specific targeted therapies, thereby optimizing treatment efficacy and minimizing unnecessary toxicity and costs [23]. Biomarkers in precision oncology encompass genetic alterations (mutations, amplifications, translocations), protein expression levels, immune markers, and functional assays [24]. Regulatory approval of targeted therapies is increasingly contingent upon companion diagnostic tests that identify biomarker-positive patients [25].



Figure 1: Precision oncology workflow from tumour biopsy/liquid biopsy collection through genomic profiling, identification of actionable alterations, biomarker-driven patient selection, targeted therapy assignment, and outcomes monitoring with serial assessment for resistance mechanisms. (17, 23, 24)

CLASSES OF TARGETED THERAPIES

Tyrosine Kinase Inhibitors

Tyrosine kinase inhibitors (TKIs) constitute the largest class of targeted therapeutics, designed to block oncogenic signaling through receptor or non-receptor tyrosine kinases [26]. TKIs are typically small molecules that compete with ATP for binding to the kinase catalytic domain, thereby preventing substrate phosphorylation and downstream pathway activation [27].

EGFR-targeted TKIs exemplify the success of precision oncology in non-small cell lung cancer (NSCLC). First-generation EGFR TKIs (gefitinib, erlotinib) demonstrated superior efficacy compared to chemotherapy in EGFR-mutant NSCLC, with objective response rates exceeding 70% and progression-free survival of 9-13 months [28]. Third-generation TKIs such as osimertinib, designed to overcome T790M-mediated resistance, further improved outcomes with median progression-free survival of 18.9 months in the FLAURA trial [29].

ALK inhibitors represent another paradigm of TKI evolution in precision oncology. The ALK fusion oncogene, identified in approximately 5% of NSCLC, is effectively targeted by multiple generations of ALK TKIs (30). First-generation crizotinib established proof-of-concept, while next-generation agents (ceritinib, alectinib, brigatinib, lorlatinib) demonstrated improved CNS penetration and activity against resistance mutations, sequentially extending survival outcomes [31].

Table 2: Major Targeted Therapies with Genomic Biomarkers and Clinical Outcomes

Drug Class	Agent	Molecular Target/Biomarker	Cancer Type	Key Trial	ORR (%)	Median PFS (months)	Median OS (months)	Reference
EGFR TKI (3rd gen)	Osimertinib	EGFR exon 19del/L858R	NSCLC	FLAURA	80	18.9	38.6	[29]
ALK TKI (2nd gen)	Alectinib	ALK rearrangement	NSCLC	ALEX	82.9	34.8	Not reached	[31]
BRAF inhibitor	Dabrafenib + Trametinib	BRAF V600E	Melanoma	COMBI-v	64	11.4	25.1	[72]
RET inhibitor	Selpercatinib	RET fusion	NSCLC, Thyroid	LIBRETTO-001	64–85	16.5–22	Not reached	[21]
HER2 ADC	Trastuzumab deruxtecan	HER2-positive/low	Breast cancer	DESTINY-Breast04	52.6	9.9	23.4	[35]
NTRK inhibitor	Larotrectinib	NTRK1/2/3 fusion	Tissue-agnostic	Basket trials	75	28.0	Not reached	[73]
BCR-ABL TKI	Imatinib	BCR-ABL1 fusion	CML	IRIS	87	Not reached	Not reached	[12]
Anti-HER2 mAb	Trastuzumab	HER2 amplification	Breast cancer	HERA	N/A	N/A	HR 0.66	[33]
PARP inhibitor	Olaparib	BRCA1/2 mutation	Ovarian, Breast, Pancreatic	SOLO-1, OlympiA	60–77	13.8–37.2	Improved	[74]
MET inhibitor	Capmatinib	MET exon 14 skipping	NSCLC	GEOMETRY mono-1	68	12.4	Not reached	[75]

Abbreviations: TKI, tyrosine kinase inhibitor; ADC, antibody-drug conjugate; mAb, monoclonal antibody; ORR, objective response rate; PFS, progression-free survival; OS, overall survival; NSCLC, non-small cell lung cancer; CML, chronic myeloid leukemia; HR, hazard ratio; N/A, not applicable

Monoclonal Antibodies and Antibody-Drug Conjugates

Monoclonal antibodies (mAbs) represent another major class of targeted therapeutics, functioning through diverse mechanisms including receptor blockade, immune-mediated cytotoxicity, and targeted drug delivery [32]. Trastuzumab, targeting HER2-overexpressing breast cancers, pioneered this approach and remains a cornerstone therapy, improving overall survival when combined with chemotherapy [33].

Antibody-drug conjugates (ADCs) combine the targeting specificity of monoclonal antibodies with cytotoxic payloads delivered selectively to cancer cells (34). Recent FDA approvals including trastuzumab deruxtecan for HER2-positive and HER2-low breast cancer, and enfortumab vedotin for urothelial carcinoma demonstrate the expanding therapeutic potential of ADCs [35]. These agents achieve superior efficacy compared to chemotherapy alone while potentially reducing systemic toxicity through targeted drug delivery [36].

Immune Checkpoint Inhibitors and Predictive Biomarkers

Immune checkpoint inhibitors (ICIs) have revolutionized treatment across multiple cancer types by restoring anti-tumor immune responses [37]. While not traditionally considered targeted therapy, ICIs exemplify precision oncology principles through biomarker-guided patient selection [38]. PD-L1 expression, tumor mutational burden (TMB), microsatellite instability (MSI-H), and mismatch repair deficiency (dMMR) have emerged as predictive biomarkers for ICI efficacy [39].

The FDA's tissue-agnostic approval of pembrolizumab for TMB-high or MSI-H/dMMR tumors represents a landmark in precision oncology, prioritizing molecular characteristics over anatomical origin [40]. Comprehensive genomic profiling enables identification of these predictive biomarkers

alongside targetable oncogenic drivers, facilitating integrated treatment selection [41].



Figure 2: Molecular mechanisms of major targeted therapy classes including tyrosine kinase inhibitors, monoclonal antibodies, antibody-drug conjugates, and immune checkpoint inhibitors. [26, 32, 37, 38]

CLINICAL OUTCOMES AND EVIDENCE BASE

Improved Progression-Free and Overall Survival

Multiple randomized controlled trials and real-world evidence studies have demonstrated superior outcomes with genomically-matched targeted therapies compared to conventional chemotherapy. Meta-analyses of precision oncology trials reveal significantly improved progression-free survival (hazard ratio 0.63, 95% CI 0.56-0.71) and higher objective response rates (odds ratio 2.48, 95% CI 2.02-3.05) with matched targeted therapies [42].

The SHIVA trial, though initially disappointing, provided important insights regarding biomarker selection and therapy matching strategies [43]. Subsequent studies with more stringent molecular matching criteria, including IMPACT and TAPUR trials, demonstrated meaningful clinical benefits in biomarker-selected populations [44]. Platform trials such as NCI-MATCH, MPACT, and Lung-MAP have established infrastructure for efficient evaluation of multiple biomarker-therapy matches in basket and umbrella trial designs [45].

Quality of Life and Toxicity Profiles

Targeted therapies generally demonstrate more favorable toxicity profiles compared to conventional chemotherapy, translating to improved quality of life outcomes [46]. While targeted agents have characteristic adverse effects (e.g., EGFR TKI-associated rash, ALK inhibitor visual disturbances), these are typically manageable with supportive care and dose modifications [47]. Patient-reported outcome measures from precision oncology trials consistently demonstrate preservation of functional status and symptom control with targeted therapies [48].

Cost-Effectiveness Considerations

Despite higher drug acquisition costs, targeted therapies may demonstrate favorable cost-effectiveness through improved efficacy, reduced hospitalization, and decreased use of supportive care medications [49]. Pharmacoeconomic analyses of genomically-guided therapy selection suggest potential healthcare cost savings through avoidance of ineffective treatments and more efficient treatment sequencing [50]. However, access disparities remain significant, particularly in low- and middle-income countries where molecular diagnostic infrastructure and drug availability are limited [51].

TABLE 3: Common Adverse Events and Management Strategies for Major Targeted Therapy Classes

Therapy Class	Representative Agent	Common Adverse Events (Grade ≥3)	Incidence (%)	Management Strategies	Impact on Quality of Life	Reference
EGFR TKIs	Osimertinib	Diarrhea, rash, paronychia, stomatitis	10–15	Dose modification, topical steroids, prophylactic antibiotics, supportive care	Generally well-tolerated; skin toxicity manageable	[29, 76]
ALK TKIs	Alectinib	Visual disturbances, elevated liver enzymes, edema	15–20	Dose reduction, hepatic function monitoring, diuretics	Minimal impact; visual effects reversible	[31, 76]
BRAF/MEK inhibitors	Dabrafenib + Trametinib	Pyrexia, rash, decreased ejection fraction	20–25	Dose interruption, NSAIDs, cardiac monitoring, dermatologic care	Manageable with supportive interventions	[72]
Anti-HER2 mAbs	Trastuzumab	Cardiac dysfunction, infusion reactions	2–5	Cardiac monitoring (LVEF), premedication, rate reduction	Low toxicity; preserved QoL	[33, 77]
HER2 ADCs	Trastuzumab deruxtecan	Interstitial lung disease, nausea, myelosuppression	10–15	Early detection (CT monitoring), dose holds, growth factors	Requires vigilant monitoring	[35]
PARP inhibitors	Olaparib	Anemia, fatigue, nausea	15–20	Dose modification, transfusion support, antiemetics	Fatigue impacts daily activities	[74]
Immune checkpoint inhibitors	Pembrolizumab	Immune-related AEs (colitis, pneumonitis, hepatitis)	10–20	Corticosteroids, immunosuppressants, permanent discontinuation if severe	Variable; some irAEs significantly impact QoL	[78, 79]
RET inhibitors	Selpercatinib	Hypertension, elevated AST/ALT, QT prolongation	10–15	Antihypertensives, LFT monitoring, ECG surveillance	Generally tolerable	[21]
NTRK inhibitors	Larotrectinib	Dizziness, fatigue, elevated liver enzymes		Dose adjustments, symptomatic management	Favorable tolerability profile	[73]

Abbreviations: TKI, tyrosine kinase inhibitor; mAb, monoclonal antibody; ADC, antibody-drug conjugate; AE, adverse event; NSAIDs, non-steroidal anti-inflammatory drugs; LVEF, left ventricular ejection fraction; QoL, quality of life; CT, computed tomography; irAEs, immune-related adverse events; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LFT, liver function tests; ECG, electrocardiogram

MECHANISMS OF RESISTANCE AND STRATEGIES FOR OVERCOMING THERAPEUTIC FAILURE

Acquired Resistance Mechanisms

Despite initial efficacy, virtually all targeted therapies eventually encounter resistance through diverse molecular mechanisms [52]. On-target resistance occurs through secondary mutations in the target protein that prevent drug binding while preserving kinase activity, exemplified by T790M in EGFR-mutant NSCLC and T315I in BCR-ABL-positive CML [53]. Off-target resistance mechanisms include activation of bypass signaling pathways, histological transformation, and phenotypic plasticity [54].

Serial tumor sampling and ctDNA analysis enable identification of resistance mechanisms, informing subsequent treatment selection [55]. The development of next-generation TKIs specifically designed to overcome resistance mutations demonstrates the value of resistance mechanism elucidation. Osimertinib effectively targets T790M-mediated resistance, while fourth-generation EGFR inhibitors are in development to address C797S mutations [56].

Tumor Heterogeneity and Clonal Evolution

Intratumoral heterogeneity, both spatial and temporal, represents a major challenge for precision oncology [57]. Multi-region sequencing studies reveal that actionable mutations may be heterogeneously distributed across tumor

regions and metastatic sites, potentially limiting efficacy of single-agent targeted therapies [58]. Liquid biopsy technologies partially address this challenge by sampling DNA from multiple tumor sites, providing a more comprehensive genomic landscape [59].

Combination Therapeutic Strategies

Rational combination strategies targeting multiple pathways or incorporating different therapeutic modalities represent promising approaches for improving outcomes and delaying resistance [60]. Combinations of TKIs with immune checkpoint inhibitors have demonstrated synergistic activity in select contexts, exemplified by pembrolizumab plus lenvatinib in endometrial cancer [61]. Similarly, vertical pathway inhibition through combinations of MEK and BRAF inhibitors in BRAF-mutant melanoma has improved progression-free survival compared to single-agent therapy [62].



Figure 3: Mechanisms of acquired resistance to targeted therapies and strategies to overcome them, including on-target mutations, bypass pathway activation, histological transformation, tumor heterogeneity, and corresponding therapeutic approaches. References :[52, 54, 57, 60]

FUTURE DIRECTIONS AND EMERGING TECHNOLOGIES

Artificial Intelligence and Machine Learning Applications

Artificial intelligence (AI) and machine learning algorithms are increasingly integrated into precision oncology workflows for variant interpretation, therapy selection, and outcome prediction [63]. AI-powered platforms can analyze complex genomic data in conjunction with clinical variables, pathology images, and radiological findings to generate integrated therapeutic recommendations [64]. Deep learning approaches have demonstrated accuracy comparable to expert oncologists in predicting treatment responses and identifying novel biomarker-therapy associations [65].

Functional Precision Medicine Approaches

Functional precision medicine involves testing patient-derived tumor cells or organoids against panels of therapeutic agents to identify effective treatments [66]. Patient-derived xenograft models and organoid cultures enable ex vivo evaluation of drug sensitivity, complementing genomic profiling with functional validation [67]. The PARIS trial demonstrated feasibility of functional drug screening to guide treatment selection in advanced cancers, with correlation between ex vivo sensitivity and clinical response [68].

Expanding Access in Resource-Limited Settings

Addressing disparities in access to precision oncology represents a critical challenge and ethical imperative [69]. Strategies include development of lower-cost genomic profiling platforms, establishment of regional molecular diagnostic laboratories, telemedicine-enabled tumor boards, and tiered therapeutic approaches utilizing available targeted agents [70]. International collaborations and data sharing initiatives can accelerate knowledge translation and optimize resource allocation in diverse healthcare settings [71].

CONCLUSION

Precision oncology has fundamentally transformed cancer treatment through integration of tumor genomics with targeted therapeutic selection. Evidence consistently demonstrates improved outcomes with genomically-matched therapies compared to conventional approaches, including superior progression-free survival, overall survival, and quality of life. Multiple classes of targeted therapeutics—tyrosine kinase inhibitors, monoclonal antibodies, antibody-drug conjugates, and immune checkpoint inhibitors—exemplify the successful translation of molecular insights into clinical benefit.

Comprehensive genomic profiling technologies, including tissue-based NGS and liquid biopsy approaches, enable identification of actionable alterations and guide biomarker-driven patient selection. However, significant challenges remain, including acquired resistance mechanisms, tumor heterogeneity, high costs, and limited access in resource-limited settings. Emerging strategies including rational combination therapies, serial molecular monitoring, artificial intelligence-guided treatment selection, and functional precision medicine approaches hold promise for further optimizing outcomes.

The continued evolution of precision oncology requires sustained investment in molecular diagnostic infrastructure, multi-disciplinary expertise development, clinical trial innovation, and equitable access initiatives. As our

understanding of cancer biology deepens and therapeutic armamentarium expands, genomics-guided treatment selection will increasingly become the standard of care across cancer types, ultimately realizing the vision of truly personalized cancer therapy.

Author Contributions

The author has significantly contributed to the study's conception, design, data collection, analysis, and interpretation. All authors were involved in writing the manuscript or critically reviewing it for its intellectual value. They have reviewed and approved the final version for submission and publication and accept full responsibility for the content and integrity of the work.

Financial Support

The authors declare that no external funding was received for this study.

Conflicts of Interest

The authors state that there are no financial, personal, or professional conflicts of interest associated with this research.

Ethical Approvals

This research did not involve the use of human participants or animal subjects and therefore did not require ethical clearance

Publisher's Note

The Journal stays neutral about jurisdictional claims in published maps and institutional affiliations

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660
2. Debela DT, Muzazu SG, Heraro KD, Ndalama MT, Mesele BW, Haile DC, et al. New approaches and procedures for cancer treatment: Current perspectives. SAGE Open Med. 2021;9:20503121211034366. doi: 10.1177/20503121211034366
3. Tsimberidou AM, Fountzilas E, Nikanjam M, Kurzrock R. Review of precision cancer medicine: Evolution of the treatment paradigm. Cancer Treat Rev. 2020;86:102019. doi: 10.1016/j.ctrv.2020.102019
4. Schwaederle M, Zhao M, Lee JJ, Eggermont AM, Schilsky RL, Mendelsohn J, et al. Impact of precision medicine in diverse cancers: A meta-analysis of phase II clinical trials. J Clin Oncol. 2015;33(32):3817–3825. doi: 10.1200/JCO.2015.61.5997
5. Manolio TA, Fowler DM, Starita LM, Haendel MA, MacArthur DG, Biesecker LG, et al. Bedside back to bench: building bridges between basic and clinical genomic research. Cell. 2017;169(1):6–12. doi: 10.1016/j.cell.2017.03.005
6. Martincorena I, Campbell PJ. Somatic mutation in cancer and normal cells. Science. 2015;349(6255):1483–1489. doi: 10.1126/science.aab4082
7. Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast cancer. Nat Rev Dis Primers. 2019;5(1):66. doi: 10.1038/s41572-019-0111-2
8. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–752. doi: 10.1038/35021093
9. Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446–454. doi: 10.1038/nature25183
10. Padma VV. An overview of targeted cancer therapy. Biomedicine (Taipei). 2015;5(4):19. doi: 10.7603/s40681-015-0019-4
11. Baudino TA. Targeted cancer therapy: The next generation of cancer treatment. Curr Drug Discov Technol. 2015;12(1):3–20. doi: 10.2174/1570163812666150602144310
12. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408–2417. doi: 10.1056/NEJMoa062867
13. Cheng DT, Mitchell TN, Zehir A, Shah RH, Benayed R, Syed A, et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn. 2015;17(3):251–264. doi: 10.1016/j.jmoldx.2014.12.006
14. Chakravarty D, Johnson A, Sklar J, Lindeman NI, Moore K, Ganesan S, et al. Somatic genomic testing in patients with metastatic or advanced cancer: ASCO provisional clinical opinion. J Clin Oncol. 2022;40(11):1231–1258. doi: 10.1200/JCO.21.02767
15. Flaherty KT, Gray RJ, Chen AP, Li S, McShane LM, Patton D, et al. Molecular landscape and actionable alterations in a genomically guided cancer clinical trial: National Cancer Institute Molecular Analysis for Therapy Choice. J Clin Oncol. 2020;38(33):3883–3894. doi: 10.1200/JCO.19.03010
16. Massard C, Michiels S, Ferté C, Le Deley MC, Lacroix L, Hollebecque A, et al. High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: Results of the MOSCATO 01 trial. Cancer Discov. 2017;7(6):586–595. doi: 10.1158/2159-8290.CD-16-1396
17. Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev

Clin Oncol. 2017;14(9):531–548. doi: 10.1038/nrclinonc.2017.14
18. Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17(4):223–238. doi: 10.1038/nrc.2017.7
19. Leighl NB, Page RD, Raymond VM, Daniel DB, Divers SG, Reckamp KL, et al. Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer. Clin Cancer Res. 2019;25(15):4691–4700. doi: 10.1158/1078-0432.CCR-19-0624
20. Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic — implementation issues and future challenges. Nat Rev Clin Oncol. 2021;18(5):297–312. doi: 10.1038/s41571-020-00457-x
21. Drilon A, Oxnard GR, Tan DSW, Loong HHF, Johnson M, Gainor J, et al. Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer. N Engl J Med. 2020;383(9):813–824. doi: 10.1056/NEJMoa2005653
22. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985–990. doi: 10.1038/nm.1789
23. Goossens N, Nakagawa S, Sun X, Hoshida Y. Cancer biomarker discovery and validation. Transl Cancer Res. 2015;4(3):256–269. doi: 10.3978/j.issn.2218-676X.2015.06.04
24. Henry NL, Hayes DF. Cancer biomarkers. Mol Oncol. 2012;6(2):140–146. doi: 10.1016/j.molonc.2012.01.010
25. Jørgensen JT. Companion and complementary diagnostics: clinical and regulatory perspectives. Trends Cancer. 2016;2(12):706–712. doi: 10.1016/j.trecan.2016.10.013
26. Bhullar KS, Lagarón NO, McGowan EM, Parmar I, Jha A, Hubbard BP, et al. Kinase-targeted cancer therapies: progress, challenges and future directions. Mol Cancer. 2018;17(1):48. doi: 10.1186/s12943-018-0804-2
27. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer. 2009;9(1):28–39. doi: 10.1038/nrc2559
28. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380–2388. doi: 10.1056/NEJMoa0909530
29. Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113–125. doi: 10.1056/NEJMoa1713137
30. Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383(21):2018–2029. doi: 10.1056/NEJMoa2027187
31. Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377(9):829–838. doi: 10.1056/NEJMoa1704795
32. Weiner GJ. Building better monoclonal antibody-based therapeutics. Nat Rev Cancer. 2015;15(6):361–370. doi: 10.1038/nrc3930
33. Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, et al. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017;389(10075):1195–1205. doi: 10.1016/S0140-6736(16)32616-2
34. Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18(6):327–344. doi: 10.1038/s41571-021-00470-8
35. Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9–20. doi: 10.1056/NEJMoa2203690
36. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–1355. doi: 10.1126/science.aar4060
37. Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16(5):275–287. doi: 10.1038/nrc.2016.36
38. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors. J Clin Oncol. 2010;28(19):3167–3175. doi: 10.1200/JCO.2009.26.7609
39. Buttner R, Longshore JW, Lopez-Rios F, Merkelbach-Bruse S, Normanno N, Rouleau E, et al. Implementing TMB measurement in clinical practice: considerations on assay requirements. ESMO Open. 2019;4(1):e000442. doi: 10.1136/esmoopen-2018-000442
40. Lemery S, Keegan P, Pazdur R. First FDA approval agnostic of cancer site — when a biomarker defines the indication. N Engl J Med. 2017;377(15):1409–1412. doi: 10.1056/NEJMp1709968
41. Merino DM, McShane LM, Fabrizio D, Funari V, Chen SJ, White JR, et al. Establishing guidelines to harmonize tumor mutational burden (TMB). J Immunother Cancer. 2020;8(1):e000147. doi: 10.1136/jitc-2019-000147
42. Schwaederle M, Zhao M, Lee JJ, Lazar V, Leyland-Jones B, Schilsky RL, et al. Association of biomarker-based treatment strategies with response rates and progression-free survival in refractory malignant neoplasms: a meta-analysis. JAMA Oncol.

2016;2(11):1452–1459. doi: 10.1001/jamaoncol.2016.2129

43. Le Tourneau C, Delord JP, Goncalves A, Gavoille C, Dubot C, Isambert N, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015;16(13):1324–1334. doi: 10.1016/S1470-2045(15)00188-6
44. Stockley TL, Oza AM, Berman HK, Leighl NB, Knox JJ, Shepherd FA, et al. Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. Genome Med. 2016;8(1):109. doi: 10.1186/s13073-016-0364-2
45. Renfro LA, Sargent DJ. Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples. Ann Oncol. 2017;28(1):34–43. doi: 10.1093/annonc/mdw413
46. Cella D, Grunwald V, Escudier B, Hammers HJ, George S, Nathan P, et al. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214). Eur Urol. 2019;76(4):443–452. doi: 10.1016/j.eururo.2019.07.017
47. Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011;19(8):1079–1095. doi: 10.1007/s00520-011-1197-6
48. Kluetz PG, Chingos DT, Basch EM, Mitchell SA. Patient-reported outcomes in cancer clinical trials: measuring symptomatic adverse events with the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Am Soc Clin Oncol Educ Book. 2016;35:67–73. doi: 10.14694/EDBK_155960
49. Zafar SY, Newcomer LN, McCarthy J, Pepper JK, Ubel PA, Polite BN. How should we intervene when the costs of cancer care are financially catastrophic? J Oncol Pract. 2016;12(2):e159–e164. doi: 10.1200/JOP.2015.007500
50. Handorf EA, Bekelman JE, Bhatt DL, Jayasuriya S, Sproch M, Damle R, et al. Economic analysis of next-generation sequencing versus standard-of-care in advanced non-small-cell lung cancer. Eur J Health Econ. 2019;20(9):1327–1336.
51. Prasad V. Perspective: The precision-oncology illusion. Nature. 2016;537(7619):S63. doi: 10.1038/537S63a
52. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13(10):714–726. doi: 10.1038/nrc3599
53. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352(8):786–792. doi: 10.1056/NEJMoa044238
54. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2(3):e73. doi: 10.1371/journal.pmed.0020073
55. Oxnard GR, Paweletz CP, Kuang Y, Mach SL, O'Connell A, Messineo MM, et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res. 2014;20(6):1698–1705. doi: 10.1158/1078-0432.CCR-13-2482
56. Janne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372(18):1689–1699. doi: 10.1056/NEJMoa1411817
57. McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell. 2017;168(4):613–628. doi: 10.1016/j.cell.2017.01.018
58. Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883–892. doi: 10.1056/NEJMoa1113205
59. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24. doi: 10.1126/scitranslmed.3007094
60. Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol. 2012;30(7):679–692. doi: 10.1038/nbt.2284
61. Makker V, Colombo N, Casado Herraez A, Santin AD, Colomba E, Miller DS, et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med. 2022;386(5):437–448. doi: 10.1056/NEJMoa2108330
62. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30–39. doi: 10.1056/NEJMoa1412690
63. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44–56. doi: 10.1038/s41591-018-0300-7
64. Kather JN, Pearson AT, Halama N, Jager D, Krause J, Loosen SH, et al. Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer. Nat Med. 2019;25(7):1054–1056. doi: 10.1038/s41591-019-0462-y
65. Esteva A, Kuprel B, Novoa RA, Ko J, Swetter SM, Blau HM, et al. Dermatologist-level classification of skin cancer with deep neural networks. Nature. 2017;542(7639):115–118. doi: 10.1038/nature21056

66. Hirata E, Sahai E. Tumor microenvironment and differential responses to therapy. Cold Spring Harb Perspect Med. 2017;7(7):a026781. doi: 10.1101/cshperspect.a026781
67. Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernandez-Mateos J, Khan K, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 2018;359(6378):920–926. doi: 10.1126/science.aao2774
68. Pemovska T, Kontro M, Yadav B, Edgren H, Eldfors S, Szwajda A, et al. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov. 2013;3(12):1416–1429. doi: 10.1158/2159-8290.CD-13-0350
69. Chan KKW, Saluja R, Delos Santos K, Lien K, Shah K, Cramarossa G, et al. Oral targeted therapy for advanced non-small cell lung cancer: a systematic review and meta-analysis. Int J Cancer. 2016;139(6):1345–1356. doi: 10.1002/ijc.30156
70. El-Deiry WS, Goldberg RM, Lenz HJ, Shields AF, Gibney GT, Tan AR, et al. The current state of molecular testing in the treatment of patients with solid tumors, 2019. CA Cancer J Clin. 2019;69(4):305–343. doi: 10.3322/caac.21560
71. Lawler M, Alsina D, Adams RA, Anderson AS, Brown G, Fearnhead NS, et al. Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer. Gut. 2018;67(1):179–193. doi: 10.1136/gutjnl-2017-314741
72. Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019;381(7):626–636. doi: 10.1056/NEJMoa1904059
73. Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378(8):731–739. doi: 10.1056/NEJMoa1714448
74. Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495–2505. doi: 10.1056/NEJMoa1810858
75. Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, et al. Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer. N Engl J Med. 2020;383(10):944–957. doi: 10.1056/NEJMoa2002787
76. Reck M, Mellemgaard A, Bhatt DL, Popat S, Rudd RM. Treatment of non-small-cell lung cancer with erlotinib/gefitinib: a toxicity review. Expert Rev Anticancer Ther. 2010;10(1):67–76. doi: 10.1586/era.09.171
77. Anota A, Savina M, Bascoul-Mollevi C, Bonnetain F. QoL-PROD: a stable methodology to analyze health-related quality of life in oncology through time to definitive deterioration in health-related quality of life score. Stat Methods Med Res. 2017;26(6):2675–2690. doi: 10.1177/0962280215601015
78. Doroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021;18(6):345–362. doi: 10.1038/s41571-021-00473-5
79. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–168. doi: 10.1056/NEJMra1703481

How to cite this article

Egege, S. E., Oladosu, M. A., Abah, M. A., Olufosoye, B. O., & Udeka, C. D. (2026). *Precision oncology: How targeted therapies based on tumor genomics improve treatment outcomes*. *Science Archives, 7*(2), 192–203. https://doi.org/10.47587/SA.2026.7218